Fang Liu - BrightGene Bio Accounting Supervisor

688166 Stock   30.92  1.21  4.07%   

Executive

Fang Liu is Accounting Supervisor of BrightGene Bio Medical
Address Building C25-28, Suzhou, China, 215123
Phone86 512 6262 0988
Webhttps://www.bright-gene.com

BrightGene Bio Management Efficiency

The company has return on total asset (ROA) of 0.0227 % which means that it generated a profit of $0.0227 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.06 %, meaning that it generated $0.06 on every $100 dollars invested by stockholders. BrightGene Bio's management efficiency ratios could be used to measure how well BrightGene Bio manages its routine affairs as well as how well it operates its assets and liabilities. At present, BrightGene Bio's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 3.9 B, whereas Net Tangible Assets are forecasted to decline to about 1.2 B.

Similar Executives

Showing other executives

EXECUTIVE Age

Ye LiGRG Banking Equipment
54
Chen LuPeoples Insurance of
51
Shangyou ZengPeoples Insurance of
N/A
Anping FuPeoples Insurance of
62
Dong WeiGRG Banking Equipment
47
Wenying ChangTianshui Huatian Technology
59
Xiangqun DingPeoples Insurance of
60
Yong ZhouTianshui Huatian Technology
56
ACIS ACSPeoples Insurance of
47
Kesheng HanPeoples Insurance of
58
Yongsheng XieGRG Banking Equipment
49
Jianhua YaoGRG Banking Equipment
49
Xin TangGuangzhou Dongfang Hotel
52
Zheng DingquanGuangzhou Dongfang Hotel
49
Baiqing ZhouJiangsu Financial Leasing
45
Tie ZhangTianshui Huatian Technology
60
Qiang ZhuJiangsu Financial Leasing
59
Qing ShiPeoples Insurance of
N/A
Hua XieGRG Banking Equipment
48
Yong ZhongGRG Banking Equipment
51
Yongsheng GaoQilu Bank Co
48
BrightGene Bio Medical (688166) is traded on Shanghai Stock Exchange in China and employs 1,155 people. BrightGene Bio is listed under Biotechnology category by Fama And French industry classification.

Management Performance

BrightGene Bio Medical Leadership Team

Elected by the shareholders, the BrightGene Bio's board of directors comprises two types of representatives: BrightGene Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BrightGene. The board's role is to monitor BrightGene Bio's management team and ensure that shareholders' interests are well served. BrightGene Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BrightGene Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
Fang Liu, Accounting Supervisor
Nan Ding, Board Secretary
Jiandong Yuan, Chairman GM
Kai Li, Deputy Manager
Zhengye Wang, Deputy Manager
Yuanlai Zou, Financial Director

BrightGene Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BrightGene Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in BrightGene Stock

BrightGene Bio financial ratios help investors to determine whether BrightGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BrightGene with respect to the benefits of owning BrightGene Bio security.